CELL & GENE THERAPY INSIGHTS

Spotlight

Viral vector bioprocessing

Apr 2021
Guest Editor:
Anindya Dasgupta, Director, Vector Development at Expression Therapeutics
Anindya Dasgupta
Director, Vector Development at Expression Therapeutics

Expert Insight


Innovator Insight


Commentary


Interview


Podcast

Improving AAV vector manufacture: a question of scale

Silke Wissing,
Juliana Coronel,
Jans Wölfel,
David Mainwaring,
Amar Joshi
29 April 2021
Podcast

FastFacts


Infographic


Report

Interview


Shelfie

On my bookshelf...

Qasim Rafiq
16 March 2021
Shelfie

On my bookshelf...

Robert Deans
3 March 2021
Shelfie

Report

Perspective

Current status and future perspective of gene therapy products in Japan

Yoshiaki Maruyama,
Akira Sakurai,
Masaki Kasai,
Shinichi Noda,
Futaba Honda
11 March 2021
Perspective

Interview

Examining Health Canada’s agile new approach to regulating Advanced Therapeutic Products

Elizabeth Toller,
Liz Anne Gillham-Eisen,
Nadine Kolas
19 March 2021
Interview

Other articles

Webinars

FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Mathieu Porte
Mathieu Porte, BioProduction R&D Manager, Polyplus-transfection
Elisa Da Silva Ferrada
Elisa Da Silva Ferrada, USP Process Development Lead Scientist, Viralgen Vector Core (VVC)
Valerie Lang
Valerie Lang, Production Manger, Viralgen VC
24 March 2021
Webinar
Scalable suspension LVV production platforms for cell and gene therapy

Scalable suspension LVV production platforms for cell and gene therapy

Suparna Sanyal
Suparna Sanyal, Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec
Michael Haller
Michael Haller, Senior R&D Scientist, Viral Vector Process Development, Lonza Pharma & Biotec
Young Shin
Young Shin, R&D Principal Scientist, Cell & Gene Technologies, Lonza Pharma & Biotec
13 April 2021
Webinar
Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Mats Lundgren
Mats Lundgren, Customer Applications Director, Life Sciences, Cytiva
Peter Guterstam
Peter Guterstam, Product Manager, Next Generation Resins & Technologies, Cytiva
Henrik Ihre
Henrik Ihre, Director Strategic Technologies, Cytiva
18 May 2021
Webinar
Key considerations for maximizing LV and AAV production in transient transfection workflows

Key considerations for maximizing LV and AAV production in transient transfection workflows

Leisha Kopp
Leisha Kopp, Applications Scientist, Mirus Bio
Dr. Beth Larimore
Dr. Beth Larimore, Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc
Anindya Dasgupta
Anindya Dasgupta, Director of Vector Development, Expression Therapeutics
Nolan Sutherland
Nolan Sutherland, Scientist, Bluebird Bio
9 June 2021
Webinar